-
Product Insights
Cumplidor-Alpha Field, Colombia
Cumplidor-Alpha upstream field is located in Putumayo, Colombia. The upstream field is owned by Gran Tierra Colombia Inc. It is operated by Gran Tierra Colombia Inc. The project started its operations in 2016. Cumplidor-Alpha Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves and capital and operating costs. We also provide...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Alpha-1 Proteinase Inhibitor (Human) Second Generation in Alpha-1 Antitrypsin Deficiency (A1AD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Alpha-1 Proteinase Inhibitor (Human) Second Generation in Alpha-1 Antitrypsin Deficiency (A1AD)Drug Details:Alpha-1 proteinase inhibitor (human) is...
-
Product Insights
North Field Alpha Field, Qatar
North Field Alpha is located in Arabian Gulf, Qatar. The upstream field is owned by QatarEnergy. It is operated by QatarEnergy. The project started its operations in 1991. North Field Alpha Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves and capital and operating costs. We also provide proprietary forecasts of...
-
Product Insights
Tommeliten Alpha Upstream Project , Norway
Tommeliten Alpha upstream project is located in North Sea, Norway. The upstream project is owned by ConocoPhillips Skandinavia AS (28.25%); PGNIG Upstream Norway AS (42.25%); TotalEnergies EP Norge AS (20.25%); Var Energi ASA (9.25%). It will be operated by ConocoPhillips Skandinavia AS. The project is currently in the planned stage and is expected to start operations in 2024. Tommeliten Alpha Upstream profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Interferon Alpha in Warts
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Interferon Alpha in WartsDrug Details:Interferon alpha (IFN) is under development for the treatment of coronavirus disease...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GMCN-508A in Alpha Thalassaemia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GMCN-508A in Alpha Thalassaemia Drug Details: GMCN-508A is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SLN-124 in Alpha Thalassaemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SLN-124 in Alpha ThalassaemiaDrug Details: SLN-124 is under development for the treatment of hereditary hemochromatosis, alpha/beta...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – alpha-dihydrotetrabenazine in Tardive Dyskinesia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. alpha-dihydrotetrabenazine in Tardive Dyskinesia Drug Details: Alpha-dihydrotetrabenazine is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Mitapivat Sulfate in Alpha Thalassaemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Mitapivat Sulfate in Alpha ThalassaemiaDrug Details:Mitapivat sulfate (Pyrukynd) act as anti anemic agent. It is formulated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ck1 Alpha Degrader in Hematological Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Ck1 Alpha Degrader in Hematological TumorDrug Details:CK1 alpha degrader is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Alvelestat in Alpha-1 Antitrypsin Deficiency (A1AD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Alvelestat in Alpha-1 Antitrypsin Deficiency (A1AD)Drug Details:Alvelestat is under development for the treatment of graft-versus-host disease,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Alpha-1 Proteinase Inhibitor (Human) in Emphysema
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Alpha-1 Proteinase Inhibitor (Human) in EmphysemaDrug Details:Alpha1-proteinase inhibitor human (Prolastin, Trypsone, Pulmolast, Lynspad) also known as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – INBRX-101 in Alpha-1 Antitrypsin Deficiency (A1AD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.INBRX-101 in Alpha-1 Antitrypsin Deficiency (A1AD)Drug Details:INBRX-101 is under the development for the treatment of alpha-1...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Fazirsiran Sodium in Alpha-1 Antitrypsin Deficiency (A1AD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Fazirsiran Sodium in Alpha-1 Antitrypsin Deficiency (A1AD)Drug Details:ARO-AAT is under development for the treatment of liver...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VX-668 in Alpha-1 Antitrypsin Deficiency (A1AD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.VX-668 in Alpha-1 Antitrypsin Deficiency (A1AD)Drug Details:VX-668 is under development for the treatment of alpha 1...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VX-864 in Alpha-1 Antitrypsin Deficiency (A1AD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.VX-864 in Alpha-1 Antitrypsin Deficiency (A1AD)Drug Details:VX-864 is under development for the treatment of alpha-1 antitrypsin...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VX-634 in Alpha-1 Antitrypsin Deficiency (A1AD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.VX-634 in Alpha-1 Antitrypsin Deficiency (A1AD)Drug Details:VX-634 is under development for the treatment of alpha-1 antitrypsin...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PHP-303 in Alpha-1 Antitrypsin Deficiency (A1AD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PHP-303 in Alpha-1 Antitrypsin Deficiency (A1AD)Drug Details:PHP-303 (BAY-858501) is under development for the treatment of alpha-1...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CONV 01-alpha in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CONV 01-alpha in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:CONV 01-alpha (225Ac-J591) is under development for...
-
Company Profile
![]()
Alpha and Omega Semiconductor Limited – Company Profile
Alpha and Omega Semiconductor Limited (AOS) is engaged in the design, development and supply of power semiconductors. It offers power discrete products including low, medium, and high voltage power metal-oxide-semiconductor field-effect transistors (MOSFETs). The company's products are used in notebooks, desktop and tablet personal computers (PCs), servers, flat panel displays, televisions (TVs), graphics cards, game boxes, chargers, battery packs, power supplies, e-bikes, motor controls, smart phones, and networking equipment. The company has its operations in the US, China, Hong Kong,...
Add to Basket
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.